NCIt definition : An Fc-engineered bispecific antibody directed against the human negative immunoregulatory
checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and
lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint
inhibitory and antineoplastic activities. Upon administration, bavunalimab targets
and binds to both CTLA-4 and LAG-3 expressed on T-cells in the tumor microenvironment
(TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin
superfamily (IgSF); they are overexpressed by regulatory T-cells (Tregs) in the TME
where they downregulate T-cell activation and proliferation. Dual checkpoint blockade
of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation
more than the blockade of either immune checkpoint receptor alone. The engineered
Fc domain increases the stability and half-life of the antibody.;
UNII : 3PT70X17VS;
CAS number : 2329669-78-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2329669-78-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)